FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Indication

Myelodysplastic Syndromes

Clinical and regulatory intelligence for Myelodysplastic Syndromes with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Relevant assets

azacitidine →

Relevant companies

No related entities indexed yet.

Recent signals(1)

ClinicalJuly 3, 2026

Phase II/III Trial Evaluates Azacitidine with Lenalidomide or Vorinostat in Myelodysplastic Syndromes

A randomized phase II/III trial is investigating the efficacy of azacitidine combined with lenalidomide or vorinostat in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Hematology →

Myelodysplastic Syndromes →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.